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Abstract
Neuroblastoma (NB) is a pediatric extracranial tumor
characterized by downregulation of human leukocyte
antigen class I and defects of the antigen processing
machinery, two features that make it an appropriate
target for natural killer (NK)-mediated lysis. NKG2D
is an activating immunoreceptor expressed by cyto-
toxic T lymphocytes and NK cells. The ligands for
NKG2D are the major histocompatibility complex class
I–related chain (MIC)A and MICB glycoproteins, and
the UL-16–binding proteins (ULBPs). Here, the ex-
pression of NKG2D ligands was investigated in human
primary NB tumors and cell lines because scanty
information is available on this issue. MICA, MICB, and
ULBP transcripts were found in most tumors and cell
lines. MICA protein was detected in some NB cell lines
but not in primary tumors. A soluble form of MICA
(sMICA) was identified in most patient sera and in
some cell line supernatants. sMICA downregulated
surface NKG2D in normal peripheral blood CD8+ cells
and decreased NK-mediated killing of MICA+ NB cells.
MICB was detected exclusively in the cytosol of
primary tumors and cell lines. Approximately 50%
of primary tumors expressed ULBP-2, but not ULBP-1
or -3. ULBP-3 was expressed in 5 of 9 cell lines,
ULBP-2 in 2 of 9, whereas ULBP-1 was never detected.
These studies delineate novel potential pathways of
tumor escape and immunodeficiency in NB.
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Introduction
Natural killer (NK) cells mediate early innate immune
responses against tumor and virally infected cells [1,2].
NK cells kill efficiently transformed cells that have down-
regulated expression of human leukocyte antigen (HLA)
class I molecules [3]. This phenomenon has been explained
by the missing-self recognition hypothesis [3]. The activat-
ing receptors involved in NK cell–mediated cytotoxicity are
the NKp46, NKp44, and NKp30 natural cytotoxicity recep-
tors (NCRs), which belong to the immunoglobulin superfamily
[4], and NKG2D.
NKG2D is a C type lectin-like molecule expressed by all NK
cells, g/y T cells, and CD8 T cells in humans. NKG2D ligands
are not expressed in normal cells, but are upregulated upon
viral and bacterial infections, transformation, and oxidative
stress [5–7]. In humans, NKG2D ligands are the MHC class
I–related chain (MIC)A and MICB molecules and the more
recently identified family of cytomegalovirus UL-16 binding
proteins (ULBPs) [8, 9]. The efficiency of NKG2D-mediated
lysis by NK cells has been shown to correlate with the surface
density of its ligands on target cells [10]. Recently, it has been
reported that soluble MICA (sMICA) and MICB are released in
sera from patients with different malignancies and downregu-
late effector cell–associated NKG2D [11,12].
Neuroblastoma (NB) is the most common extracranial tumor
of childhood, often refractory to conventional treatments in-
cluding surgery, chemotherapy, and radiotherapy [13]. It has
been known for a long time that HLA class I antigens are
virtually undetectable in NB cell lines and can be upregulated
by interferon-g (IFN-g) [14,15]. Recently, we have demonstrat-
ed multiple defects in the antigen processing machinery of
human NB cell lines and primary tumors, suggesting that
protocols of T cell–based immunotherapy may be not appro-
priate for this tumor (L. R., manuscript submitted; Ref. [14]).
However, NB cells can represent excellent targets for NK-
mediated cytotoxicity, provided that specific activating ligands
are expressed on the surface of tumor cells [16].
To the best of our knowledge, scanty information is available
about the expression of NKG2D activating ligands in human
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NB. Only two cell lines were analyzed and both were found to
express a MICA/ULBP phenotype [10]. In this study, we
have investigated the potential role of NKG2D in immune
surveillance against NB by analyzing expression of the
various NKG2D ligands on panels of primary tumors and
NB cell lines, the release of sMICA, and its impact on
recognition of tumor cells by cytotoxic effectors.
Materials and Methods
Patients
This investigation was performed after approval by a local
institutional review board.
The criteria used for diagnosis and evaluation of disease
extension have been reported elsewhere [17]. Briefly, diag-
nosis was based on histologic grounds or on bone marrow
infiltration by tumor cells, usually associated with elevated
urinary catecholamine excretion.
The disease was staged according to the criteria of the
International Neuroblastoma Staging System (INSS) [17].
They include the measurement of primary tumor size with
ultrasonography and/or computed tomography, a bone
marrow study by at least one aspirate, a skeletal study by
plain X-ray survey and/or technetium 99m DPM scintigraphy,
and the measurement of urinary vanillylmandelic and homo-
vanillic acids and of serum lactate dehydrogenase [17].
Tissues and Cell Lines
The primary neuroblastic tumors and the sera used in this
study were obtained from patients at diagnosis before the
implementation of any therapy. An intestinal biopsy was
obtained from a patient affected with ulcerative colitis and
used for preliminary titration of anti-MICA and anti-MICB
monoclonal antibodies (mAbs). Anti-ULBP mAbs were titrat-
ed in preliminary experiments performed with human tonsil
tissue sections [8].
Tissue samples were fixed in 20% buffered formalin,
routinely processed, and embedded in paraffin. One part of
some of the lesions was snap frozen in liquid nitrogen and
stored at 80jC. For mRNA analysis, primary NB cells were
isolated as described [18]. Briefly, NB cell suspensions were
first incubated with an anti-GD2 mAb and then positively
selected by immunomagnetic beads coated with anti –
mouse immunoglobulin antibodies (Immunotech, Marseille,
France), according to the instructions of the manufacturer.
The source of the anti-GD2 mAb (IgG2a) was the superna-
tant of the ME361-S2a murine hybridoma, purchased from
ATCC, Manassas, VA.
The ACN, GI-ME-N, HTLA-230, GI-CA-N, LAN-5, LAN-1,
SK-N-BE-2c, SK-N-SH, and SH-SY-5Y neuroblastoma cell
lines, the human cervical carcinoma HeLa cell line, the
human leukemia U937 cell line, and the human fibroblast
293T strain cell lines were cultured in RPMI 1640 medium
(Sigma, St. Louis, MO) supplemented with L-glutamine,
penicillin/streptomycin, nonessential amino acids, and 10%
FBS (Sigma) (complete medium). To investigate the release
of sMICA, ACN, GI-ME-N, GI-CA-N, and HeLa cell lines
were cultured at subconfluence in RPMI 1640 medium
without serum for 48 hours. Then the supernatants were
collected, concentrated 10 times with CentriconR Plus-20
(Millipore Corporation, Bedford, MA), and used as indicated.
Monoclonal Antibodies and Flow Cytometry
To characterize the surface and intracellular expression
of NKG2D ligands in tumor cell lines, the following mAbs
were used: BAM195 (anti-MICA, IgG1; IST, Genova, Italy)
[5]; M295 (anti–ULBP-1, IgG1), M311 (anti–ULBP-2, IgG1),
and M551 (anti–ULBP-3, IgG1), kindly donated by Dr. David
Cosman (Amgen, Seattle, WA) [8]; the mAb clones AUMO1
(anti–ULBP-1, IgG1), BUMO2 (anti–ULBP-2, IgG1), and
CUMO2 (anti–ULBP-3, IgM, produced by one of us [A. S.]
[11]). The anti-MICB mAb S-JJ5 was generated from a
BALB/c mouse immunized with multiple injections of recom-
binant MICB protein and a peptide corresponding to residues
187 to 203 of MICB. The specificity of mAb S-JJ5 for MICB
was shown by its specific reactivity with COS cells trans-
fected with MICB cDNA.
IgG1 or IgM isotype-matched irrelevant mAbs (Southern
Biotechnology Associates, Birmingham, AL) were tested as
negative controls. All of the experiments were performed
using both sets of anti-ULBPmAbs; the results here reported
were obtained with the Amgen mAbs because these per-
formed better in immunohistochemical studies.
Phycoerythrin-conjugated AffiniPure F(ab’)2 fragments of
goat anti–mouse IgG or IgM antibodies were purchased
from Jackson Immunoresearch Laboratories (West Grove,
PA). Intracellular staining of cell lines was performed as
described [19]. Briefly, cells were washed three times with
PBS (Sigma) containing 1% FBS (staining buffer) and fixed
with 2% paraformaldehyde at room temperature for
20 minutes. Then, cells were washed twice with staining
buffer and incubated in permeabilization buffer (PBS, 1%
FBS, 0.1% saponin, Sigma) for 30 minutes at room temper-
ature. Cells (5  105 per tube) were next incubated with the
primary mAb for 30 minutes at room temperature, then
washed twice with permeabilization buffer and incubated
with PE-conjugated F(ab’)2 fragments of goat anti–mouse
IgG or IgM antibodies (Jackson) for 30 minutes at room
temperature. Cells were then washed twice in permeabiliza-
tion buffer and resuspended in staining buffer before being
analyzed by flow cytometry using a FACScan instrument (BD
Biosciences, San Jose, CA).
For cell surface staining, cells were sequentially incubat-
ed with optimal amounts of test mAb and with PE-conjugated
F(ab’)2 fragments of goat anti–mouse IgG or IgM antibodies,
and analyzed by flow cytometry. Isotype- and subclass-
matched mouse Ig were used as negative controls in all
the experiments. CellQuest software (BD Biosciences) was
used for data analysis. The results of flow cytometry experi-
ments are expressed as either mean fluorescence intensity
(MFI) or mean relative fluorescence intensity (MRFI), i.e., the
ratio between the MFI of cells stained with the selected mAb
and the MFI of cells stained with isotype-matched mouse Ig.
MFI values of the isotype control and of test mAbs were used
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to evaluate whether the differences between the peaks of
cells were statistically significant with respect to control. The
Kolmogorov-Smirnov test for the analysis of histograms was
used, according to the CellQuest software user’s guide.
MICA and MICB expression in NB cell lines was also
investigated by immunocytochemistry. Cells (2  105 per
slide) were cytocentrifuged, dried in air, and fixed in 10%
buffered formalin for 10 minutes. Endogenous peroxidase
activity was blocked by 10-minute incubation at room tem-
perature with methanol containing 3% H2O2. Cytospins were
then incubated overnight at 4jCwith optimal amounts of anti-
MICA or -MICB mAbs, or with isotype- and subclass-
matched mouse Ig. Cytospins were subsequently washed
twice in Optimax Wash Buffer (Menarini Diagnostics,
Firenze, Italy) and incubated for 30 minutes at room temper-
ature with Dako Envision System HRP Mouse (Dako,
Glostrup, Denmark). After washing in Optimax Wash Buffer,
peroxidase activity was detected by incubating cytospins for
6 to 10 minutes at room temperature with Dako Liquid DAB
Substrate Chromogen System (Dako). Cytospins were final-
ly counterstained with Mayer’s hematoxylin (Sigma).
In some experiments, NB cells were admixed with IL-2–
activated NK cells (see below) at a 1:10 ratio, centrifuged,
and incubated for 10 minutes at 37jC before being stained
for surface and cytosolic MICB and analyzed by flow
cytometry.
Reverse Transcription-Polymerase Chain Reaction
RNA was extracted from freshly isolated or cultured
cells using RNeasy Mini Kit from Qiagen GmbH (Hilden,
Germany) and subjected to reverse transcriptase-polymer-
ase chain reaction (RT-PCR) as reported [20]. Primer
sequences and profiles of amplification were the following:
glyceraldehyde phosphate dehydrogenase (G3PDH) 5V
ACATCGCTCAGAACACCTATGG and 3V GGGTCTACA-
TGGCAACTGTGAG; CD45 5V CCTACAGACCCAGTTTCC
and 3V GGCAATCTTTTTCTGTCT; DRb 5V CTCCAG-
CATGGTGTGTCTGA and 3V GGAGGTTGTGGTGCTG-
CAGG; MICA 5V CAGGGACTTGACAGGGAAC and 3V
CCTCTCCTCGGCAAATCCT; MICB 5V ACCGAGGACTT-
GACAGAGA and 3V CCGCTGATGTTTTCTTCT; ULBP-1
5V TCTGTGCCTCCCGCTTCTG and 3V GCCTTGGG-
TTGGGTTGTGC; ULBP-2 5V GCAACAAGACAGTCACACC
and 3V AGCAGGGGAGGATGATGAG; ULBP-3 5V TCCA-
TCGGCTTCACACTCA and 3V GTGAGGTCCAGAGC-
CAGGT. Amplification profile was 94jC for 1 minute,
annealing 60jC (G3PDH), 49jC (CD45), 55jC (DRb, MICA,
and ULBP-3), 59jC (MICB), 57jC (ULBP-1), 53jC (ULBP-2)
for 1 minute and extension at 72jC for 1 minute. Each cycle
of amplification was repeated 35 times. Ten microliters of
each sample was electrophoresed through a 1% agarose gel
containing ethidium bromide. The specificity of amplification
products was checked by confirming the known base-pair
sequence length.
Immunohistochemical Staining of Primary NB Tissues
Immunohistochemical staining of tissue sections was
performed using the Envision System horseradish peroxi-
dase (HRP) Mouse (Dako). Briefly, 5-mm-thick sections were
cut from formalin-fixed, paraffin-embedded blocks, deparaffi-
nized with xylene, and rehydrated by passages through
decreasing concentrations of ethanol (from 100% to 80%).
Endogenous peroxidase activity was blocked by a 30-minute
incubation at room temperature with methanol containing
3% H2O2. Tissue sections were then incubated at 98jC for
40 minutes in citrate buffer (pH 6.0) for antigen retrieval
(ChemMate, Dako). After rinsing in Optimax Wash Buffer
(Menarini Diagnostics), tissue sections were incubated over-
night at 4jC with optimal amounts of test mAbs (anti-MICB,
anti-ULBP-1, -2, and -3) or isotype- and subclass-matched
mouse Ig. Tissue sections were washed twice in Optimax
Wash Buffer and incubated for 30 minutes at room temper-
ature with Dako Envision System HRPMouse. After washing
in Optimax Wash Buffer, peroxidase activity was detected
by incubating tissue sections for 6 to 10 minutes at room
temperature with Dako Liquid DAB Substrate Chromogen
System (Dako). Tissue sections were counterstained with
Mayer’s hematoxylin (Sigma).
Frozen tissue sections were used as a substrate for
immunohistochemical staining with anti-MICA mAb because
this mAb did not work on paraffin-embedded, formalin-fixed
tissue sections.
Serial tissue sections were stained with NB84 (Dako) and
CD45 mAbs (UCHL1, Dako), which detect neuroblasts and
cells of hematopoietic origin, respectively. Areas containing
at least 80% to 90% neuroblasts were selected for the
analysis of MICA, MICB, and ULBP expression. To this
end, these areas were first inspected at low magnification
and then carefully analyzed at higher magnification (63).
The percentage of stained tumor cells in each lesion was
evaluated independently by two investigators. The variation
between the results obtained by these investigators was less
than 10%. Results were scored as negative or positive, when
the percentage of stained tumor cells in each microscopic
area was less than 25% or more than 25%, respectively. The
inclusion of each tumor sample in one of the above scores
was based on the score of the microscopic area containing
the highest percentage of mAb positive neuroblasts.
ELISA
A commercial ELISA Kit by IMMATICS Biotechnologies
(Tubingen, Germany) was used to detect sMICA. The assay
was performed following the manufacturer’s protocol. Briefly,
two anti-MICA mAbs binding to different MICA domains were
used. Plates were coated with the capture anti-MICA mAb
AMO-1 at 2 mg/ml in PBS + 0.1% BSA (Sigma) overnight at
4jC, and blocked by addition of 100 ml of 15% BSA for
2 hours at 37jC. After washings, the standard (recombinant
MICA*04 in 0.1% BSA-PBS) and the samples were added
and the plates were incubated for 2 hours at 37jC. For anal-
ysis of patient sera and cell supernatants, the samples were
diluted 1:3 in 0.1% BSA-PBS. After incubation, plates were
washed, the detection mAb BAMO-3 at 5 mg/ml in 0.1% BSA-
PBS was added, and incubation was continued for 2 hours
at 37jC. After washing, an anti–mouse IgG2a-HRP (Santa
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Cruz Biotechnology, Santa Cruz, CA), diluted 1:10000 in
0.1% BSA-PBS, was added and incubation was continued
for an additional hour at 37jC. Plates were then washed
and developed using 3,3V, 5,5V-tetramethylbenzidine (TMB)
liquid (Sigma). Absorbance was measured at 450 nm and
results were expressed as picograms per milliliter.
Immunoblot Analysis
ACN, GI-ME-N, and HeLa cells were lysed under reduc-
ing conditions as described [21]. Briefly, 100-mg protein
aliquots were diluted in 250 mM sodium phosphate buffer,
pH 8, 2% 50 mM EDTA, and 0.2% sodium dodecyl sulfate
(SDS), boiled 5 minutes, subjected to 10% SDS-polyacryl-
amide gel electrophoresis (PAGE), and run in parallel with
prestained SDS-PAGE standard (Biorad, Hercules, CA). The
resolved proteins were blotted onto nitrocellulose mem-
branes Hybond-C extra (Amersham International, Little
Chalfont, Buckinghamshire, UK), and anti-MICB (S-JJ5)
mAb was used to localize the corresponding polypeptides
on the blots. Peroxidase-conjugated goat anti–mouse anti-
body was used as secondary antibody (Santa Cruz). Im-
mune complexes were visualized with the use of an
enhanced chemiluminescence system (Amersham) accord-
ing to manufacturer’s instructions.
Preparation and Culture of NK-Enriched Cell Suspensions
Peripheral blood mononuclear cells (PBMCs) were
obtained by Ficoll-Hypaque density gradient centrifugation
of heparinized normal blood samples. PBMCs were washed
and resuspended in RPMI 1640 complete medium and
depleted of monocytes by adherence to plastic for 1 hour
at 37jC. To enrich for NK cells, PBMCs were depleted of
T lymphocytes by rosetting with neuraminidase-treated
sheep erythrocytes and subsequently incubated with CD14
(Dako) and anti–HLA-DR (D1.12 ATCC) mAbs (30 minutes
at 4jC), followed by goat anti-mouse IgG–coated magnetic
beads (Immunotech) according to the manufacturer’s
instructions. The resulting cell fractions, which contained
consistently at least 90% CD3 and CD56+ NK cells, as
assessed by double staining with CD3 and CD56 (BD
Biosciences) mAbs, were cultured for 4 days at 37jC
in complete medium supplemented with 500 U/ml rIL-2
(Proleukin-Chiron Italia s.r.l., Milan, Italy).
Modulation of NKG2D
Normal PBMCs were incubated with MICA+ sera from NB
patients or MICA sera from healthy donors diluted 1:2 for
24 hours at 37jC. Cells were then stained with anti-NKG2D
purified mAb (R&D Systems, Minneapolis, MN) followed by a
PE-conjugated goat anti–mouse IgG1 as secondary mAb
(BD Biosciences) and with CD8-FITC (BD Biosciences).
Cells were finally analyzed by flow cytometry gating on
CD8+ cells.
Cytotoxicity Assays
NK cells cultured for 4 days at 37jC with rIL-2 were tested
for cytotoxic activity in a 4-hour 51Cr-release assay as
previously described [22]. Briefly, MICA+ ACN neuroblasto-
ma cells were labeled with Na2
51CrO4 (Amersham) for 1 hour
at 37jC and washed three times. Labeled cells were then
added to effector cells in V-bottom microwells at a 40:1
effector to target ratio in a final volume of 200 ml. To assess
the interference of sMICA in NKG2D-dependent lysis, acti-
vated NK cells were first incubated overnight in the presence
or in the absence of sera (1:2 final dilution) from MICA+ NB
patients or control sera (1:2 final dilution), or in the presence
of NB cell lines supernatants (10 concentrated). In some
experiments, a 1-ml aliquot of sMICA+ NB serum or of ACN
cell line supernatant was preincubated with immunomag-
netic beads (Immunotech), which had been coated with anti-
MICA mAb, for 3 hours at room temperature in continuous
rotation before being tested in the above assay.
In some experiments, target ACN cells were also incu-
bated for 15 minutes at 37jC with anti-MICA mAb (20 mg/ml)
before the addition of effector cells. Chromium release was
measured in the supernatants (100 ml) harvested after
4 hours incubation at 37jC. Percent specific lysis was
calculated as described [22].
Statistics
Data were analyzed with the Mann-Whitney nonpara-
metric test. A value was considered significant when P was
lower than .05.
Results
MICA, MICB, ULBP-1, -2, and -3 mRNA Expression in
Primary Neuroblasts and NB Cell Lines
RT-PCR analysis of MICA, MICB, ULBP-1, -2, and -3
gene expression was performed on primary neuroblasts and
NB cell lines. Primary neuroblasts were isolated from eight
tumors (three localized and five disseminated) by positive
selection with immunomagnetic beads according to the
expression of surface GD2, a disialoganglioside expressed
with high specificity on human NB cells [23]. The purity of
GD2+ neuroblasts was checked by RT-PCR with CD45 and
HLA-DRb gene-specific primers [18]. Because these genes
are not expressed in NB cells, all the following experiments
were performed only with GD2+, CD45 and HLA-DRb cells
(Figure 1, panel A). All NB samples consistently expressed
MICA, MICB, and ULBP-1 mRNA; ULBP-2 and -3 transcripts
were detected in 50% of the cases (Figure 1, panel B). With
one exception, expression of ULBP-2 and -3 transcripts was
observed in the same samples (Figure 1, panel B). Figure 1,
panel A, shows the pattern of MICA, MICB, ULBP-1, -2, and
-3 mRNA expression in GD2+ cell fractions from a localized
(Pt1) and a metastatic (Pt2) NB tumors.
ULBP-1, -2, -3 and MICB mRNA were detected in 9 of 9,
8 of 9, 8 of 9, and 7 of 9 NB cell lines, respectively (Table 1).
In contrast, MICA transcript was expressed only in the SK-N-
SH, GI-ME-N, GI-CA-N and ACN cell lines (Table 1).
MICA, MICB, ULBP-1, -2, and -3 Protein Expression in
Primary NB Tumors and Cell Lines
Paraffin-embedded tissue sections from 22 newly diag-
nosed, Schwannian stroma–poor, primary NB were stained
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in the immunoperoxidase reaction with an MICB-specific
mAb (S-JJ5). Expression of the ULBP proteins was investi-
gated in 12 formalin-fixed, paraffin-embedded tumors. MICA
expression was analyzed in frozen tissue sections from eight
tumors because BAM195 anti-MICAmAb does not react with
formalin-fixed, paraffin-embedded tissues.
Figure 2, panel A, shows a representative experiment
performed with the anti-MICB mAb, in which most of the
tumor cells in every lesion displayed strong cytosolic stain-
ing. For comparison, the staining of a representative NB cell
line (ACN) with anti-MICB mAb, as assessed by immunocy-
tochemistry, is shown in the inset in panel A. Again, a strong
cytosolic staining was obtained using a technique similar to
immunohistochemistry.
Figure 2, panel B, shows the proportion of NB tumors
testing positive for MICB expression. As apparent, such
expression did not correlate with the pattern of disease
presentation, i.e., localized or metastatic disease.
All NB lesions tested negative for MICA. In these experi-
ments, positive control, represented by an intestinal biopsy
from an ulcerative colitis patient, displayed evident MICA
staining (data not shown).
ULBP-2 was found to be expressed in approximately
50% of tumors tested, whereas ULBP-1 and -3 were never
detected in any lesion. In ULBP-2+ tumors, most cells were
stained and the pattern of staining ranged from moderate to
intense in the different samples. Figure 2, panel C, shows a
representative staining of NB tissue with anti–ULBP-2 mAb.
The expression of ULBP-2 was unrelated to disease presen-
tation (data not shown). In Figure 2, panel D, a negative
control stained with an isotype- and subclass-matched irrel-
evant antibody is shown.
Expression of MICA, MICB, ULBP-1, -2, and -3 proteins
was next investigated in a panel of NB cell lines by flow
cytometry. MICB was detected on the surface of the U937
cell line tested as positive control, but not on that of any
NB cell line (Figure 3, panels A and B). Conversely, MICB
was found in the cytosol of five of these cell lines (Figure 3,
panel A).
The possibility that MICB could be shuttled from the
cytosol to cell surface upon interaction of NB cell lines with
IL-2–activated NK cells was investigated using the ACN cell
line. However, these experiments showed that no surface
MICB expression was detectable under these conditions
(data not shown).
Figure 1. MICA, MICB, ULBP-1, -2, and -3 gene expression in primary GD2+ NB cells as assessed by RT-PCR. In panel A, the results obtained with two
representative tumors out of the eight analyzed are shown. Neuroblasts were isolated as GD2+ cells by immunomagnetic bead manipulation. From left to right:
MW = molecular weight markers; NC = negative control, represented by water in place of cDNA; PC = positive control, represented by 1) the GD2 cell fraction
isolated from primary NB tumors for CD45 and DR gene expression, 2) HeLa cells for MICA gene expression, 3) U937 cells for MICB gene expression, and 4)
293T cells for ULBP gene expression; Pt 1 = NB cells from patient 1; Pt 2 = NB cells from patient 2. The first upper panel shows the amplification product of the
G3PDH housekeeping gene tested as control. On the right side of each panel, the expected MWs of the amplified bands are shown. Panel B summarizes the
results obtained from the study of the eight primary NB tumors.
Table 1. MICA, MICB, ULBP-1, -2, and -3 mRNA Expression by NB Cell
Lines.
NB cell lines MICA MICB ULBP-1 ULBP-2 ULBP-3
HTLA-230  + + + +
SK-N-SH + + + + +
SH-SY-5Y   + + +
SK-N-BE-2c  + +  
ACN + + + + +
GI-CA-N + + + + +
GI-ME-N + + + + +
LAN-5   + + +
LAN-1  + + + +
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To prove unambiguously that staining of NB cells by the
MICB-specific mAb S-JJ5 reflected reactivity with MICB
protein, lysates of the NB cell lines ACN and GI-ME-N were
tested with mAb S-JJ5 in Western blotting. The cell line U937
was used as a positive control. All cell lines showed a band of
43 kDa and two fainter bands of 45 and 55 kDa. These
molecular forms of the MICB protein fall in the range reported
by Dunn et al. [24]. Figure 3, panel C, shows a representative
experiment out of the three performed, in which ACN NB
cells and U937 cells were tested. These results indicate the
MICB bands detected by Western blot were the same in NB
cell lines, which retain the protein in the cytosol, and in U937
cells, which express it on the cell surface.
MICA was not detected either in the cytosol or on the
surface of any NB cell line, with the exception of ACN and GI-
CA-N cells, which, in analogy to HeLa cells tested as positive
control (data not shown), expressed surface MICA at high
intensity (Figure 3, panel B). ACN and GI-CA-N cells also
displayed intracellular staining for MICA (data not shown).
Similar patterns ofMICA expressionwere observedwhen cell
lines were stained by immunocytochemistry (not shown).
ULBP-2 was detected on the surface of the GI-CA-N and
GI-ME-N cells, ULBP-3 on the surface of HTLA-230, SK-N-
SH, ACN, GI-CA-N, and GI-ME-N cells (Figure 3, panel B).
Cell lines testing negative for surface expression of ULBP-2
or -3 did not express these ligands intracellularly. ULBP-1
was never detected either on the surface or in the cytosol of
any cell line (Figure 3, panel B). All anti-ULBP mAbs stained
the cell surface of the 293T cell line tested as positive control
(data not shown).
In conclusion, the above data demonstrated downregula-
tion of the ligands for the NKG2D-activating receptor on the
surface of primary neuroblasts and NB cell lines, suggesting
that tumor cells can often escape from the control of NKG2D+
cytotoxic effectors.
Release of sMICA by NB Tumors
Next, MICA release in NB patient sera was investigated
by ELISA. Serum samples of 51 healthy donors and 20 NB
patients were tested. Thirteen of the latter sera were from
patients with metastatic disease, whereas 7 were from
patients with localized disease.
The majority of sera from normal individuals contained
levels of sMICA close to the detection limit of the ELISA
(10 pg/ml), with a median of 10 pg/ml (Figure 4, panels A
and B). sMICA in sera from NB patients ranged between
Figure 2. MICB and ULBP-2 protein expression in primary human NB tumors. Immunoperoxidase staining of formalin-fixed, paraffin-embedded NB primary
tumors. Panel A shows one representative staining for anti-MICB mAb (S-JJ5). Inset panel shows a representative staining of ACN NB cell line for anti-MICB mAb
by immunocytochemistry. Panel B summarizes the data obtained from immunohistochemical analysis of 17 disseminated and 5 localized NB primary tumors. Panel
C shows one representative staining for anti-ULBP-2 mAb (M311). Panel D shows negative control stained with an isotype- and subclass-matched irrelevant
antibody. Arrows indicate neuroblasts stained by the above mAbs, arrowheads indicate negatively stained lymphoid infiltrates. Original magnification, 40.
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10 and 1470 pg/ml, with a median of 120 pg/ml (Figure 4,
panels A and B). The differences between the concentra-
tions of sMICA in sera from healthy donors and NB patients
were statistically significant (P < .0001), as determined by
Mann-Whitney nonparametric test (Figure 4, panel A). No
correlation was found in NB patients between sMICA serum
concentrations and disease presentation.
The presence of sMICA was also evaluated in concen-
trated culture supernatants of NB cell lines. sMICA at the
concentration of 200 and 85 pg/ml, respectively, was
detected only in supernatant of ACN and GI-CA-N cell lines,
after 48 hours culture at 37jC in serum-free medium.
Downregulation of NKG2D and Inhibition of NKG2D-
Mediated Cytolytic Activity by sMICA
We subsequently investigated the effects of sMICA on
NKG2D expression in normal PBMCs. The latter cells were
cultured in the presence of sMICA+ serum from an NB patient
or sMICA serum from a healthy donor. As shown in Figure 5,
NKG2D expression on CD8+ cells, which contain most of the
NKG2D+ cells in human peripheral blood, was consistently
reduced by PBMC incubation with serum of a NB patient
containing 740 pg/ml sMICA, but not with normal serum.
To address the functional role of sMICA with regard to
NKG2D-mediated cytolytic activity, we performed cytotoxicity
Figure 3. Surface and intracellular expression of MICB in human NB cell lines. (Panel A) The cell lines were stained with the anti-MICB mAb (S-JJ5) and
subsequently analyzed by flow cytometry as detailed in the Materials and Methods section. One representative experiment out of the three performed with similar
results is shown. Gray histograms represent surface staining and black histograms represent intracellular staining for MICB. U937 cells are shown as positive
control for MICB surface expression. Results are expressed as MRFI. The inset in the right upper side of the figure shows a representative histogram obtained by
intracellular staining of SK-N-BE-2c cells. The gray profile indicates staining with isotype-matched control mAb, whereas the black profile refers to staining with anti-
MICB mAb. Panel B summarizes the results of surface staining of the whole panel of NB cell lines with mAbs to all NKG2D ligands. (Panel C) Western blot analysis
of lysates from ACN NB cells (lane 1) and U937 human leukemia cells (lane 2) tested as positive control with anti-MICB mAb (S-JJ5). The position of molecular
weight markers is on the right side. One representative experiment out of the three performed is shown.
564 Downregulation of NKG2D Ligands in Neuroblastoma Raffaghello et al.
Neoplasia . Vol. 6, No. 5, 2004
assays using IL-2–activated NK cell populations that had
been isolated from different healthy donors as effectors,
and the surface MICA+ ACN NB cell line as target. As
shown in the representative experiment of Figure 6, ACN
cells were efficiently lysed by NK cells (70% specific lysis
at a 40:1 effector to target ratio). Cytotoxicity was partly
dependent on the MICA-NKG2D interaction because it
was consistently reduced (to 45% specific lysis) by target
cell incubation with anti-MICA mAb (BAM195) (Figure 6),
but not with control mAb (data not shown). Likewise, in-
hibition of NKG2D-mediated lysis was observed when NK
cells were preincubated with serum of NB patient con-
taining 720 pg/ml sMICA (40% specific lysis), but not with
sMICA normal serum (68% specific lysis) (Figure 6). This
inhibitory effect was abolished when sMICA+ serum of NB
patient was preincubated with anti-MICA mAb bound to im-
munomagnetic beads (72% specific lysis) (Figure 6).
In contrast, no inhibition was observed when sMICA+
serum of the same NB patient was preincubated with an
isotype- and subclass-matched mAb of irrelevant specificity
bound to immunomagnetic beads (data not shown).
sMICA+ supernatant from ACN NB cells inhibited
NKG2D-mediated lysis to a lesser extent (53% specific lysis,
data not shown) than NB patient serum. In contrast sMICA
supernatant of HTLA-230 NB cells did not effect NK-medi-
ated lysis (70%, data not shown).
These studies indicate that sMICA present in sera of NB
patients can impair NKG2D expression on cytotoxic cells and
their effector function against NKG2D ligand expressing
target cells.
Discussion
Human NB cells display low to absent expression of surface
HLA molecules, thus escaping specific T-cell recognition
[14,15,25]. This feature makes them an attractive target for
NK cell–based immunotherapy.
The NK sensitivity of NB cell lines has been known for a
long time, but recent studies have shed new light on the
mechanisms involved [26]. In particular, lysis of NB cells by
NK cell lines was found to depend on NCR expression on the
latter cells, and pretreatment of effector cells with a cocktail
of anti-NCR mAbs strongly reduced cytotoxic activity [16].
In this study we provide the first phenotypic and functional
characterization of the major ligands of NKG2D, another
activating receptor of cytotoxicity, in human NB.
Most primary NB tumors showed MICA and MICB ex-
pression both at the mRNA and protein levels, and similar
patterns were observed in a panel of NB cell lines. The MICA
protein was not detected in tumor cells, but was present in
soluble form in most NB sera; in contrast, the MICB protein
was found consistently in the cytosol, but not on the surface
of tumor cells. These patterns of MICA/MICB expression
differ from those observed in non-tumor-bearing individuals.
Thus, in the latter, MICA/MICB surface expression is induced
by inflammatory stress in intestinal epithelial cells [5, 7], and
soluble MICA and MICB are detected in serum only occa-
sionally and at very low levels [11].
Previous studies have identified sMICA in serum from
patients with different malignancies [11, 12]. In view of the
mechanism of sMICA production, operated by metalloprotei-
nase-dependent proteolytic cleavage [27], failure to detect
Figure 4. Levels of sMICA (pg/ml) in sera of NB patients and healthy donors (panel A). Serum samples of 20 NB patients and 51 healthy donors were tested by
ELISA. Panel B shows the lowest and highest values detected in both groups together with median, mean, and standard error.
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MICA expression in primary tumors may appear somewhat
unexpected. However, it is conceivable that newly formed
surface or cytosolic MICA is cleaved very quickly to generate
the soluble form, thus hindering MICA detection in tissue
sections. An additional factor that may contribute to the latter
phenomenon is the limited sensitivity of immunohistochem-
istry. This hypothesis is supported by the finding that both NB
cell lines releasing sMICA in culture supernatants showed
surface and cytosolic MICA expression, as assessed by the
more sensitive flow cytometry.
In this study, functional experiments demonstrated that
sMICA in patient sera downregulated NKG2D expression on
the surface of CD8+ cells and reduced cytotoxicity of IL-2–
activated NK cells against MICA+ target cells. These results
are consistent with various reports in different tumors [11, 12]
and point to a general strategy of immune evasion used by
malignant cells. Furthermore, other NKG2D ligands besides
MICA may be released in soluble form. Soluble MICB has
been detected in sera from patients with hematological
malignancies [11], and ULBP-1, whose transcript was found
here to be expressed in most primary tumors, may be
another candidate soluble molecule.
A novel potential strategy of immune evasion delineated
in the present investigation is the cytosolic retention of MICB
observed in primary NB tumors and cell lines. Thus, failure of
NB cells to express MICB on the cell surface would limit their
interactions with NKG2D+ cytotoxic cells.
A similar phenomenon has been demonstrated in human
tumor cell lines transfected with the UL16 cytomegalovirus
gene [24]. The UL16 protein caused MICB retention in the
Figure 5. Modulation of NKG2D expression on peripheral blood CD8+ cells from normal donors by sMICA+ serum from a NB patient. One representative
experiment out of the three performed is shown. The fluorescence intensity of NKG2D was measured on PBMCs from a healthy donor that had been untreated
(control: upper dot plot panel), incubated with sMICA normal serum (middle dot plot panel) or with sMICA+ serum of an NB patient (lower dot plot panel). NKG2D
expression was analyzed gating on CD8+ cells (boxed areas in plots on the left side of the figure). Numbers in the top right corners of plots on the right side indicate
NKG2D MFI (subtracted from background). MFI of IgG1 isotype negative control was 9 (data not shown).
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endoplasmic reticulum and the cis-Golgi apparatus, where it
inhibited the processing of MICB to mature forms [24].
The mechanism(s) involved in cytosolic sequestration of
the MICB protein in NB cells is so far unknown. Our prelim-
inary results indicate that the molecular weight of MICB was
similar in NB cell lines and in U937 cells, irrespective of MICB
expression in the cytosol of the former and on the surface of
the latter cells. These findings suggest that cytosolic MICB
retention in NB cells may be consequent to altered intracel-
lular trafficking of the protein, but this issue warrants further
investigation.
The only NKG2D ligand expressed on the surface of
primary NB tumors is ULBP-2, which was detected in half
of the cases, whereas ULBP-1 and ULBP-3 staining was
consistently negative. In NB cell lines, ULBP-3 was detected
in half of the cell lines, ULBP-2 in a small number of them,
and ULBP-1 in none. The discrepancies in the patterns of
ULBP expression between primary tumors and cell lines may
be related to changes induced by long-term culture in the
latter cells or to the different sensitivity of the detection
techniques used. Based on the current knowledge, no spe-
cific functions of individual ULBP proteins for interaction with
NK are known.
In conclusion, NB cells use multiple mechanisms to evade
the control of the host immune system. These include 1)
downregulation of MICA expression associated with produc-
tion of sMICA, 2) cytosolic sequestration of MICB, and 3)
downregulation of ULBP molecules. It is conceivable that
these very same mechanisms contribute to the pathogene-
sis of immune deficiency in NB patients, since functional
impairment of NKG2Dmay reduce the efficacy of NK cell and
CTL responses against target cells infected by pathogens,
especially viruses.
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